The uses of psychotropics in symptom management in advanced cancer

Psycho-Oncology

Volumn 7, Issue 4, 1998, Pages 346-358

  Bruera, Eduardo ^a,b   Neumann, Catherine M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DEXAMPHETAMINE; DRONABINOL; HALOPERIDOL; LEVOMEPROMAZINE; MAZINDOL; MEDROXYPROGESTERONE ACETATE; MELATONIN; METHYLPHENIDATE; MIDAZOLAM; OPIATE; PEMOLINE; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE;

CACHEXIA; CANCER PAIN; CANCER STAGING; COGNITIVE DEFECT; COMORBIDITY; DELIRIUM; DEPRESSION; DIET SUPPLEMENTATION; DROWSINESS; DRUG CHOICE; DRUG EFFECT; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; HYPOTENSION; REVIEW; TREATMENT PLANNING; TREMOR; URINE RETENTION; WEIGHT GAIN;

CACHEXIA; DISEASE PROGRESSION; HUMANS; MENTAL DISORDERS; NEOPLASMS; PAIN; PALLIATIVE CARE; PSYCHOTROPIC DRUGS;

EID: 0031853117     PISSN: 10579249     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1611(199807/08)7:4<346::AID-PON364>3.0.CO;2-8     Document Type: Review

References (106)

1. Banning, A. and Sjogren, P. (1990) Cerebral effects of long-term oral opioids in cancer patients measured by continuous reaction time. Clin. J. Pain 6, 91-95.
2. Banning, A., Sjogren, P. and Kaiser, F. (1992) Reaction time in cancer patients receiving peripherally acting analgestics alone or in combination with opioids. Acta. Anaesthesiol. Scand. 36, 480-482.
3. Beal, J.E., Olson, R. and Laubenstein, L. et al. (1995) Dronabinol as a treatment for anorexia associated weight loss in patients with AIDS, J. Pain Sympt. Manag. 10(2), 89-97.
4. Billingsley, K.G. and Alexander, H.R. (1996) The pathophysiology of cachexia in advanced cancer and AIDS, in Cachexia-Anorexia in Cancer Patients (E. Bruera and I. Higginson Eds.) Oxford University Press, Oxford, pp. 1-22.
5. Bleasel, M.D., Peterson, G.M. and Dunne, P.F. (1994) Plasma concentrations of midazolam during continuous subcutaneous administration in palliative care. Palliat. Med. 8(3), 231-236.
6. Breitbart, W. and Mermelstein, H. (1992) Pemoline: an alternative psychostimulant for the management of depressive disorders in cancer patients. Psychosomatics 33, 352-356.
7. Breitbart, W., Bruera, E., Chochinov, H. and Lynch, M. (1995) A National Cancer Institute of Canada Workshop on symptom control and supportive care in patients with advanced cancer: methodological and administrative issues. Neuropsychiatrie syndromes and psychological symptoms in patients with advanced cancer. J. Pain Sympt. Manag. 10(2), 131-141.
8. Breitbart, W., Marotta, R. and Platt, M.M. et al. (1996) A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am. J. Psychiatry 153, 231-237.
9. Breitbart, W., Chochinov, H.V. and Passik, S. (1998) Psychiatric aspects of palliative care, in Oxford Textbook of Palliative Medicine Second edition (D. Doyle, G.W.C. Hanks and N. MacDonald Eds.) Oxford University Press, Oxford, pp. 203-222.
10. Bruera, E. (1990) Symptom control in patients with cancer, in J. Psychosoc. Oncol. (G.H. Christ Ed.) Haworth Press, Binghamton, 8(2/3), 47-73.
11. Bruera, E. (1996) Patient assessment in palliative care. Cancer Treat. Rep. 22, 3-12.
12. Bruera, E. and Fainsinger, R.L. (1998) Clinical management of cachexia and anorexia, in Oxford Textbook of Palliative Medicine, Second Edition (D. Doyle, G.W.C. Hanks and N. MacDonald Eds.) Oxford University Press, Oxford, pp. 548-557.
13. Bruera, E., Roca, F., Cedaro, L., Chacon, R. and Estevez, R. (1983) Improved control of chemotherapy-induced emesis by the addition of dexamethasone in patients resistant to metoclopramide. Cancer Treat. Rep. 67(4), 381-383.
14. Bruera, E., Roca, E., Cedaro, L., Carraro, S. and Chacon, R. (1985) Action of oral methlprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat. Rep. 69(7/8), 751-754.
15. Bruera, E., Carrara, S., Roca, E., Barugel, M. and Chacon, R. (1986) Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite and activity in terminal cancer patients. Cancer Treat. Rep. 70(2), 295-298.
16. Bruera, E., Brenneis, C., Chadwick, S., Hanson, J. and MacDonald, R.N. (1987a) Methyphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat. Rep. 71(1), 67-70.
17. Bruera, E., Catz, Z., Hooper, R., Lentle, B. and MacDonald, R.N. (1987b) Chronic nausea and anorexia in patients with advanced cancer: a possible role for autonomic dysfunction. J. Pain Sympt. Manag. 2(1), 19-21.
18. Bruera, E., Brenneis, C., Michaud, M., Rafter, J., Magnan, A., Tennant, A., Hanson, J. and MacDonald, R.N. (1989a) Association between asthenia and nutritional status, lean body mass, anemia, psychometrical status and tumor mass in patients with advanced breast cancer, J. Pain Sympt. Manag. 4(2), 59-63.
19. Bruera, E., Brenneis, C., Paterson, A.H.G. and MacDonald, R.H. (1989b) Use of methlyphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J. Pain Sympt. Manag. 4(1), 3-6.
20. Bruera, E., Macmillan, K. and Hanson, J. et al. (1989c) The cognitive effects of administration of narcotic analgesics in patients with cancer pain. Pain 39, 13-16.
21. Bruera, E., Macmillan, K., Hanson, J. and MacDonald, R.N. (1989d) The Edmonton staging system for cancer pain: preliminary report. Pain 37, 203-209.
22. Bruera, E., Macmillan, K., Hanson, J., Kuehn, N. and MacDonald, R.N. (1990) A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66, 1279-1282.
23. Bruera, E., Fainsinger, R., MacEachern, T. and Hanson, J. (1992a) The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 50, 75-77.
24. Bruera, E., Miller, L., McCallion, J., Macmillan, K., Krefting, L. and Hanson, J. (1992b) Cognitive failure in patients with terminal cancer: a prospective study. J. Pain Sympt. Manag. 7(4), 192-195.
25. Bruera, E., Moyano, J., Seifert, L., Fainsinger, R.L., Hanson, J. and Suarez-Almazor, M. (1995a) The frequency of alcoholism among patients with pain due to terminal cancer. J. Pain Sympt. Manag. 10(8), 599-603.
26. Bruera, E., Schoeller, T., Wenk, R., MacEachern, T,. Marcelino, S., Suarez-Almazor, M. and Hanson, J. (1995b) A prospective multicenter assessment of the Edmonton Staging System for cancer pain. J. Pain Sympt. Manag. 10(5), 348-355.
27. Bruera, E., Ernst, S., Hagen, N., Spachynski, K., Belzile, M. and Hanson, J. (1996a) Symptomatic effects of megestrol acetate (MA): a double-blind, crossover study. Proc. ASCO 1716 #531.
28. Bruera, E., Fainsinger, R.L., Schoeller, T. and Ripamonti, C. (1996b) Rapid discontinuation of hypnotics in terminal cancer patients: A prospective study. Ann. Oncol. 7, 855-856.
29. Chiarello, R.J., Cole, J.O. (1987) The use of psychostimulants in general psychiatry: a reconsideration. Arch. Gen. Psychiatry 44, 286-295.
30. Chochinov, H.M., Wilson, K.G., Enns, M. and Lander, S. (1994) The prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgements. Am. J. Psychiatry 151, 537-540.
31. Chochinov, H.M., Wilson, K.G., Enns, M., Mowchan, N., Lander, S., Levitt, M. and Clinch, J. (1995) Desire for death in the terminally ill. Am. J. Psychiatry 152, 1185-1191.
32. Curtis, E.B., Krech, R. and Walsh, T.D. (1991) Common symptoms in patients with advanced cancer. J. Palliat. Care 7(2), 25-29.
33. DeFlorio, M. and Massie, M.J. (1995) Review of depression in cancer: gender differences. Depression 3, 66.
34. Dunlop, R. (1996) Clinical epidemiology of cancer cachexia, in Cachexia-Anorexia in Cancer Patients (E. Bruera and I. Higginson Eds.) Oxford University Press, Oxford, pp. 76-82.
35. Evans, W. and Beryner, D. (1964) A comparison of the analgesic effect of morphine, pentazocine, and a mixture of metamphetamine and pentazocine in the rat. J. New Drugs 4, 82.
36. Fainsinger, R. (1996) Pharmacological approach to cancer anorexia and cachexia, in Cachexia Anorexia in Cancer Patients (E. Bruera and I. Higginson Eds.) Oxford University Press, Oxford, pp. 128-140.
37. Fainsinger, R.L., Tapper, M. and Bruera, E. (1993) A perspective on the management of delirium in the terminally ill. J. Palliat. Care 9(3), 4-8.
38. Fernandez, F., Adams, F. and Holmes, V.F. et al. (1987) Methylphenidate for depressive disorders in cancer patients. Psychosomatics 28, 455-461.
39. Flaum, M. and Andreasen, N.C. (1997) More choices for treating voices. Lancet 350(Suppl. III), 22.
40. Foltin, R.W., Fischman, M.W. and Byrne, M.F. (1988) Effect of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11, 1-14.
41. Forrest, W., Brown, B. and Brown, C. et al. (1977) Dextroamphetamine with morphine for the treatment of postoperative pain. New Engl. J. Med. 296, 712-715.
42. Frytak, S., Moertel, C.J. and O'Fallon, J.R. et al. (1979) Delta-nine-tetrahydrocannabinol as an antimetic for patients receiving cancer chemotherapy. Ann. Int. Med. 91, 825-830.
43. Gordon, N. (1976) Reaction-times of methadone treated ex-heroin addicts. Psycho pharmacologia 16, 337-344.
44. Higginson, I. and McCarthy, M. (1989) Measuring symptoms in terminal cancer: are pain and dyspnea controlled? J. R. Soc. Med. 82, 264-267.
45. Ingham, J. and Portenoy, R.K. (1998) The measurement of pain and other symptoms, in Oxford Textbook of Palliative Medicine Second Edition (D. Doyle, G.W.C. Hanks and N. MacDonald Eds.) Oxford University Press, Oxford, pp. 203-222.
46. Ivy, A., Goetzl, F. and Burril, D. (1984) Morphine-dextroamphetamine analgesia. War Med. 6, 67.
47. Joshi, J., de Jongh, C. and Schnapper, N. et al. (1982) Amphetamine therapy for enhancing the comfort of terminally ill patients with cancer. Proc. Am. Soc. Clin. Oncol. 1, C213.
48. Kaplan, G. (1994) Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology 191(4/5), 564-568.
49. Kathol, R.G., Mutgi, A., Williams, J., Clamon, G. and Noyes, R. (1990) Diagnosis of major depression in cancer patients according to four sets of criteria. Am. J. Psychiatry 147(8), 1021-1024.
50. Katon, W. and Raskind, M. (1980) Treatment of depression in the medically ill elderly with methylphenidate. Am. J. Psychiatry 137, 963-965.
51. Klausner, J.D., Makonkawkeyoon, S. and Akarasewi, P. et al. (1996) The effect of thalidomide on the pathogenesis of human immunodeficienty virus type 1 and M tuberculosis infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11(3), 247-257.
52. Lane, M., Vogel, C.L. and Ferguson, J. et al. (1991) Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapty-induced nausea and vomiting. J. Pain Sympt. Manag. 6, 352-359.
53. Larson, E.B., Kukall, W.A., Buchner, D. and Reifler, B.V. (1987) Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann. Int. Med. 107, 169-173.
54. Leipzig, R.M., Goodman, H. and Gray, G. et al. (1987) Reversible, narcotic-associated mental status impairment impairment in patients with metastatic cancer. Pharmacology 35, 47-54.
55. Lissoni, P., Barni, S. and Tancini, G. (1994) Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin. J. Biol. Regul. Homeostatic Agents 8(4), 126-129.
56. Lissoni, P., Barni, S., Brivio, F., Rossini, F., Fumagalli, L. and Tancini, G. (1995) Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study. J. Biol. Regul. Homeostatic Agents 9(2), 52-54.
57. Lissoni, P., Paolorossi, F., Tancini, G., Barni, S., Ardizzoia, A. and Brivio, F. et al. (1996) Is there a role for melatonin in the treatment of neoplastic cachexia? Eur. J. Cancer 32A(8), 1340-1343.
58. Lombardo, W.K., Lombardo, B. and Goldstein, A. (1976) Cognitive functioning under moderate and low dosage methadone maintenance. Int. J. Addict. 11, 389-401.
59. Loprinzi, C.L., Ellison, N.M. and Schaid, D.J. et al. (1990) Controlled trial of megestrol acetate for the treatment of cancer, anorexia and cachexia. J. Natl. Cancer Inst. 82, 1127-1132.
60. Loprinzi, C.L., Michalak, J.C. and Schaid, D.J. (1993) Phase three evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J. Clin. Oncol. 11, 762-767.
61. Lucas, V.S. and Laszio, J. (1980) Delta-nine-tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy, J. Am. Med. Assoc. 243, 1241-1243.
62. Lynch, M. (1995) The assessment and prevalence of affective disorders in advanced cancer. J. Palliat. Care 11(1), 10-18.
63. MacDonald, F.C., Gough, K.J. and Nicoll, R.A.G. et al. (1989) Psychomotor effects of ketorolac in comparison with buprenorphine and diclofenac. Br. J. Pharmacol. 33, 139-146.
64. Massie, M.J., Holland, J. and Glass, E. (1983) Delirium in terminally ill cancer patient. Am. J. Psychiatry 140(8), 1048-1050.
65. Mechoulam, R., McCallum, N.K. and Lander, V. et al. (1976) Aspects of cannabis chemistry and metabolism, in The Pharmacology of Marijuana (M.C. Braude and S. Szara Eds.) Raven Press, New York, NY, pp. 39-48.
66. Moertel, C., Schutt, A.G., Reiteneier, R.J. and Hahn, R.G. (1974) Corticosteroid therapy of pre-terminal gastrointestinal cancer. Cancer 33, 1607-1609.
67. Nelson, K., Walsh, D. and Deeter, P. et al. (1994) A phase II study of delta-nine-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J. Palliat. Care 10, 14-18.
68. Olofsson, S.M., Weitzner, M.A., Valentine, A.D., Baile, W.F. and Meyers C.A. (1996) A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support. Care Cancer 4(6), 351-357.
69. Oneschuk, D. and Bruera, E. (1997) The 'dark side' of adjuvant analgesic drugs. Prog. Palliat. Care 5(1), 5-13.
70. Passik, S.D. and Portenoy, R.K. (1998) Substance abuse issues in palliative care, in Principles and Practice of Supportive Oncology (A.M. Berger, R.K. Portenoy and D.E. Weissman Eds.) Lippincott-Raven, Philadelphia, PA, pp. 513-529.
71. Payne, D.K. and Massie, M.J. (1998) Depression and anxiety, in Principles and Practice of Supportive Oncology (A.M. Berger, R.K. Portenoy, D.E. Weissman Eds.) Lippincott-Raven, Philadelphia, PA, pp. 497-511.
72. Pereira, J. and Bruera, E. (1996) Chronic nausea, in Cachexia-Anorexia in Cancer Patients (E. Bruera and I. Higginson Eds.) Oxford University Press, Oxford, pp. 23-37.
73. Pereira, J. and Bruera, E. (1997) Emerging neuropsychiatric toxicities of opioids, in J. Pharm. Care in Pain and Symptom Control - Innovations in Drug Development, Evaluation and Use (A.G. Lipman Ed.) Haworth Press, New York, 5(4), 3-29.
74. Pereira, J., Hanson, J. and Bruera, E. (1997) The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 79(4), 835-842.
75. Pilowsky, L.S., Mulligan, R.S., Acton, P.D., Ell, P.J., Costa, D.C. and Kerwin, R.W. (1997) Limbic selectivity of clozapine. Lancet 350, 490-491.
76. Plata-Salaman, C.R. (1991) Dexamethasone inhibits food intake suppression induced by low doses of interleukin-IB administered intrace-rebroventricularly. Brain Res. Bull. 27, 737-738.
77. Popiela, T., Lucchi, R. and Giongo, F. (1989) Methylprednisolone as palliative therapy for female terminal cancer patients. Eur. J. Cancer Clin. Oncol. 25, 823-829.
78. Ramani, S. and Karnad, A.B. (1996) Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer. Southern Med. J. 89(11), 1101-1103.
79. Reyes-Teran, G., Sierra-Madero, J.G., Martinez del Cerro, V., Arroyo-Figueroa, H., Pasquuetti, A. and Calva, J.J. et al. (1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial, AIDS 10(13), 1501-1507.
80. Ripamonti, C. and Bruera, E. (1996) Pain and symptom management in palliative care. Cancer Control 3(3), 204-213.
81. Ripamonti, C. and Bruera, E. (1997) CNS adverse effects of opioids in cancer patients. Guidelines for treatment. CNS Drugs 8(1), 21-37.
82. Robustelli Della Cuna, G., Pellegrini, A. and Piazzi, M. (1985) Effect of methyiprednisolone in terminal cancer patients: a prospective randomize double-blind study. Cancer Treat. Rep. 69(7/8), 751-754.
83. Saarialho-Kere, U., Mattila, M.J. and Paloheirmo, M. et al. (1987) Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur. J. Clin. Pharmacol. 33, 139-146.
84. Schmidt, H., Rush, B. and Simonian, G. et al. (1996) Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats. J. Surg. Res. 63(1), 143-146.
85. Schuler, U. and Ehninger, G. (1995) Thalidomide: Rationale for renewed uses in immunological disorders (Review). Drug Safety 12(6), 364-369.
86. Sjogren, P. and Banning, A. (1989) Pain, sedation and reaction time during long-term treatment of cancer patients with epidural opioids. Pain 39, 5-11.
87. Sjogren, P., Banning, A.M. and Larsen, T.K. et al. (1990) Postural stability during long-term treatment of cancer patients with epidural opioids. Acta Anaesthesiol. Scand. 34, 410-412.
88. Sjogren, P., Banning, A.M. and Christensen, C.B. et al. (1994) Continuous reaction time after single dose, long-term oral and epidural opioid administration. Eur. J. Anaesthesiol. 11, 95-100.
89. Smith, M.J., Breitbart, W.S. and Platt, M.M. (1995) A critique of instruments and methods to detect, diagnose, and rate delirium. J. Pain Sympt. Manag. 10, 35-77.
90. Stiefel, F. and Bruera, E. (1991) On symptom control when death is near. J. Palliat. Care 7(1), 39-41.
91. Tchekmedyian, S., Hakman, M. and Siau, J. et al. (1992) Megestrol acetate in cancer anorexia and weight loss. Cancer 69, 1268-1274.
92. Tramontant, J.M., Utaipat, U. and Molley, A. et al. (1995) Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1(4), 384-397.
93. Tune, L.E., Carr, S. and Hoag, E. et al. (1992) Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am. J. Psychiatry 149, 1393-1394.
94. Uehara, A., Sckiya, C. and Takasugi, Y. et al. (1989) Anorexia induced by interleukin 1: involvement of corticotropin-releasing factor. Am. J. Physiol. 257, R613-617.
95. Underleeider, J.T., Andrysiak, T. and Fairbanks, L. et al. (1992) Cannabis in cancer chemotherapy. Cancer 50, 636-635.
96. Vainio, A., Ollila, J. and Matikainen, E. et al. (1995) Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346, 667-670.
97. Vigano, A. and Bruera, E. (1996) Enteral and parenteral nutrition in cancer patients, in Cachexia-Anorexia in Cancer Patients (E. Bruera and I. Higginson Eds.) Oxford University Press, Oxford, pp. 110-127.
98. Wadleigh, R., Spaulding, M. and Lembersky, B. et al. (1990) Dronabinol enhancement of appetite in cancer patients. Proc. Am. Soc. Oncol. 9, 331.
99. Watanabe, S. and Bruera, E. (1994) Corticosteroids as adjuvant analgesics. J. Pain Sympt. Manag. 9(7), 442-445.
100. Weiner, M. (1980) Amphetamines, in The Pharmacological Basis of Therapeutics (A. Goodman, L. Goodman and A. Gilman Ed.) MacMillian, New York, p. 159.
101. Willcox, J., Corr, J. and Shaw, J. et al. (1984) Prednisolone as an appetite stimulant in patients with cancer. Br. Med. J. 200, 37.
102. Wilwerding, M.B., Loprinzi, C.L., Mailliard, J.A., O'Fallon, J.R., Miser, A.W., van Haelst, C., Barton, D.L., Foley, J.F. and Athman. L.M. (1995) A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support. Care Cancer 3(2), 135-138.
103. Woodruff, R. (1993) Palliative Medicine. Asperula, Melborne, pp. 3-12.
104. Woods, S.W., Tesar, G.E., Murray, G.B. and Cassem, N.H. (1986) Psychostimulant treatment of depressive disorders secondary to medical illness. J. Clin. Psychiatry 47, 12-15.
105. World Health Organization Expert Committee (1990) Report on cancer pain relief and palliative care. Technical Seriers 804, World Health Organization, Geneva, Switzerland.
106. Yee, J.D. and Berde, C.B. (1994) Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J. Pain Sympt. Manag. 9(2), 122-125.